Nat Rev Dis Primers

. 2022 Jun 1;8(1):37.

 doi: 10.1038/s41572-022-00362-w. https://pubmed.ncbi.nlm.nih.gov/35650272/

Congenital diaphragmatic hernia

Augusto Zani ^1 2, Wendy K Chung ³, Jan Deprest ^4 5, Matthew T Harting ^6 7, Tim Jancelewicz ⁸, Shaun M Kunisaki ⁹, Neil Patel ¹⁰, Lina Antounians ^11 12, Pramod S Puligandla ¹³, Richard Keijzer ^14 15

Affiliations expand

• PMID: 35650272
• DOI: 10.1038/s41572-022-00362-w

Abstract

Congenital diaphragmatic hernia (CDH) is a rare birth defect characterized by incomplete closure of the diaphragm and herniation of fetal abdominal organs into the chest that results in pulmonary hypoplasia, postnatal pulmonary hypertension owing to vascular remodelling and cardiac dysfunction. The high mortality and morbidity rates associated with CDH are directly related to the severity of cardiopulmonary pathophysiology. Although the aetiology remains unknown, CDH has a polygenic origin in approximately one-third of cases. CDH is typically diagnosed with antenatal ultrasonography, which also aids in risk stratification, alongside fetal MRI and echocardiography. At specialized centres, prenatal management includes fetal endoscopic tracheal occlusion, which is a surgical intervention aimed at promoting lung growth in utero. Postnatal management focuses on cardiopulmonary stabilization and, in severe cases, can involve extracorporeal life support. Clinical practice guidelines continue to evolve owing to the rapidly changing landscape of therapeutic options, which include pulmonary hypertension management, ventilation strategies and surgical approaches. Survivors often have long-term, multisystem morbidities, including pulmonary dysfunction, gastroesophageal reflux, musculoskeletal deformities and neurodevelopmental impairment. Emerging research focuses on small RNA species as biomarkers of severity and regenerative medicine approaches to improve fetal lung development.

© 2022. Springer Nature Limited.